The Latest Breaking News from FDA

Although it would leave federal prohibition essentially untouched, the change would facilitate medical research and dramatically reduce taxes on state-licensed suppliers.

Sage said Thursday it will cut about 40% of its workforce following a setback for depression treatment Zurzuvae. Sage stock edged higher.

With innovative approaches and cutting-edge technologies, biotech has ushered in a new era of possibilities in the medical field. Hence, investing in three fundamentally sound biotech stocks, Equillium, Inc. (EQ), Theratechnologies (THTX), and Exelixis (EXEL), could yield healthy profits. Learn more….

Abrysvo was also approved by the FDA in May 2023 to prevent RSV illness in adults 60 years and older

Texas joins a handful of states turn to the north for cheaper drugs. But feds have been slow to approve requests, three years after giving initial OK.

With the Food and Drug Administration’s Aug. 21, 2023, approval of the first vaccine against respiratory syncytial virus, or RSV, for use during late pregnancy, the U.S. will soon have a major new tool at its disposal to protect infants against the highly contagious virus.

Move came after FDA said earlier that people should ‘properly discard’ the products if they have purchased it

While schoolchildren go without needed medication, government agencies shirk responsibility by blaming manufacturers.

The pharma industry is anticipated to stay buoyed in the years to come with consistent medical breakthroughs and rising need to serve an aging population. Therefore, pharma stocks Johnson & Johnson (JNJ), Novartis AG (NVS), and Dr. Reddy's Laboratories (RDY), which possess promising pipelines, could be wise portfolio additions now.…